FDA组合式医药产品的评价管理策略分析

董江萍;马坤;孙利华

中国药学杂志 ›› 2006, Vol. 41 ›› Issue (21) : 1676-1678.

中国药学杂志 ›› 2006, Vol. 41 ›› Issue (21) : 1676-1678.
药事管理

FDA组合式医药产品的评价管理策略分析

  • 董江萍;马坤;孙利华
作者信息 +
文章历史 +

引用本文

导出引用
董江萍;马坤;孙利华. FDA组合式医药产品的评价管理策略分析[J]. 中国药学杂志, 2006, 41(21): 1676-1678

参考文献

[1] Overview of the Office of Combination Products. Http: //www.fda.gov/oc/combination/overview.html. [2] Definition of a Combination Product http//www.fda.gov/oc/combination/definition.html(21 CFR § 3.2(e),U.S). [3] FDA Proposes Rule on “Combination” Products.http://www. Fda.gov/bbs/topics/ANSWERS/2004/ANS01288.html. [4] FDA:Primary Mode of Action Assignment Flowchart[2006-07-23] . Http://www. Fda. Gov/oc/combination/pmoa.pdf. [5] FDA:Guidance for Industry and FDA Staff: Application user Fees for Combination Products. [6] FDA:Combination Products Timeliness of Premarket Review; Dispute Resolution. [7] FDA:Current Good Manufacturing Practices Practices for Combination Products. [8] FDA:http://www.fda.gov/oc/combination/howtowrite.html.

Accesses

Citation

Detail

段落导航
相关文章

/